{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:03:44Z","timestamp":1792757024681,"version":"4.5.0"},"reference-count":89,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.jneuroim.2024.578315","type":"journal-article","created":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T16:12:40Z","timestamp":1708186360000},"page":"578315","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Recent advances in the treatment of primary and secondary progressive Multiple Sclerosis"],"prefix":"10.1016","volume":"390","author":[{"given":"Shitiz","family":"Sriwastava","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Elkhooly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suban","family":"Amatya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kriti","family":"Shrestha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuf","family":"Kagzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipika","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Jaiswal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Lisak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jneuroim.2024.578315_bb0005","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2217\/nmt-2021-0058","article-title":"Updates and advances in multiple sclerosis neurotherapeutics","volume":"13","author":"Amin","year":"2023","journal-title":"Neurodegen. Dis. Manag."},{"key":"10.1016\/j.jneuroim.2024.578315_bb0010","doi-asserted-by":"crossref","first-page":"104164","DOI":"10.1016\/j.msard.2022.104164","article-title":"Does the use of the Bruton tyrosine kinase inhibitors and the c-kit inhibitor masitinib result in clinically significant outcomes among patients with various forms of multiple sclerosis?","volume":"67","author":"Arsenault","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"4","key":"10.1016\/j.jneuroim.2024.578315_bb0025","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/hmg\/ddn388","article-title":"Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis","volume":"18","author":"Baranzini","year":"2009","journal-title":"Hum. Mol. Genet."},{"issue":"15","key":"10.1016\/j.jneuroim.2024.578315_bb0030","doi-asserted-by":"crossref","first-page":"6427","DOI":"10.2147\/JIR.S389958","article-title":"The immunomodulatory functions of BTK inhibition in the central nervous system","volume":"24","author":"Cao","year":"2022","journal-title":"J. Inflamm. Res."},{"issue":"25","key":"10.1016\/j.jneuroim.2024.578315_bb0035","doi-asserted-by":"crossref","first-page":"11313","DOI":"10.1073\/pnas.1002716107","article-title":"Allosteric inhibition of macrophage migration inhibitory factor revealed by ibudilast","volume":"107","author":"Cho","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.jneuroim.2024.578315_bb0040","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0014-2999(99)00127-2","article-title":"Inhibitory effect of the neuroprotective agent idebenone on arachidonic acid metabolism in astrocytes","volume":"370","author":"Civenni","year":"1999","journal-title":"Eur. J. Pharmacol."},{"issue":"1\u20132","key":"10.1016\/j.jneuroim.2024.578315_bb0050","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jns.2012.12.009","article-title":"Mesenchymal stem cell transplantation in multiple sclerosis","volume":"333","author":"Cohen","year":"2013","journal-title":"J. Neurol. Sci."},{"issue":"20","key":"10.1016\/j.jneuroim.2024.578315_bb0055","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJM200011163432001","article-title":"Relapses and progression of disability in multiple sclerosis","volume":"343","author":"Confavreux","year":"2000","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.jneuroim.2024.578315_bb0060","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1212\/WNL.0000000000012323","article-title":"Secondary progressive Multiple Sclerosis: new insights","volume":"97","author":"Cree","year":"2021","journal-title":"Neurology."},{"issue":"10","key":"10.1016\/j.jneuroim.2024.578315_bb0065","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1177\/1352458520971819","article-title":"Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis","volume":"27","author":"Cree","year":"2021","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.jneuroim.2024.578315_bb0070","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.yrtph.2006.06.004","article-title":"Safety evaluation of alpha-lipoic acid (ALA)","volume":"46","author":"Cremer","year":"2006","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"Suppl. 1","key":"10.1016\/j.jneuroim.2024.578315_bb0075","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1191\/1352458504ms1025oa","article-title":"Natural history of primary progressive multiple sclerosis","volume":"10","author":"Ebers","year":"2004","journal-title":"Mult. Scler."},{"issue":"Pt 3","key":"10.1016\/j.jneuroim.2024.578315_bb0080","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1093\/brain\/123.3.641","article-title":"The natural history of multiple sclerosis: a geographically based study: 8: familial multiple sclerosis","volume":"123","author":"Ebers","year":"2000","journal-title":"Brain."},{"issue":"3","key":"10.1016\/j.jneuroim.2024.578315_bb0085","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1159\/000342779","article-title":"Incidence and prevalence of multiple sclerosis in the Americas: a systematic review","volume":"40","author":"Evans","year":"2013","journal-title":"Neuroepidemiology."},{"issue":"4","key":"10.1016\/j.jneuroim.2024.578315_bb0090","doi-asserted-by":"crossref","first-page":"e1164","DOI":"10.1212\/NXI.0000000000001164","article-title":"Role of Chitinase 3-like 1 as a biomarker in Multiple Sclerosis: a systematic review and Meta-analysis","volume":"9","author":"Floro","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"9","key":"10.1016\/j.jneuroim.2024.578315_bb0095","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1056\/NEJMoa1803583","article-title":"Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis","volume":"379","author":"Fox","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.jneuroim.2024.578315_bb0100","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1177\/1352458520986956","article-title":"Neurofilament light chain in a phase 2 clinical trial of ibudilast in progressive multiple sclerosis","volume":"27","author":"Fox","year":"2021","journal-title":"Mult. Scler."},{"issue":"7","key":"10.1016\/j.jneuroim.2024.578315_bb0105","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/acn3.51574","article-title":"A double-blind, randomized, placebo-controlled phase 2 trial evaluating the selective dihydroorotate dehydrogenase inhibitor vidofludimus calcium in relapsing-remitting multiple sclerosis","volume":"9","author":"Fox","year":"2022","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"5","key":"10.1016\/j.jneuroim.2024.578315_bb0110","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/ana.24497","article-title":"Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque","volume":"78","author":"Frischer","year":"2015","journal-title":"Ann. Neurol."},{"issue":"10","key":"10.1016\/j.jneuroim.2024.578315_bb0115","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1080\/13543784.2016.1221924","article-title":"Ibudilast for the treatment of multiple sclerosis","volume":"25","author":"Goodman","year":"2016","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"2","key":"10.1016\/j.jneuroim.2024.578315_bb0120","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1001\/jamaneurol.2022.4156","article-title":"Time to change the current clinical classification of Multiple Sclerosis?","volume":"80","author":"Granziera","year":"2023","journal-title":"JAMA Neurol."},{"issue":"10111","key":"10.1016\/j.jneuroim.2024.578315_bb0125","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1016\/S0140-6736(17)32346-2","article-title":"Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial","volume":"390","author":"Green","year":"2017","journal-title":"Lancet."},{"issue":"12","key":"10.1016\/j.jneuroim.2024.578315_bb0130","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1136\/jnnp-2014-307712","article-title":"Multiple sclerosis deep grey matter: the relation between demyelination, neurodegeneration, inflammation and iron","volume":"85","author":"Haider","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"9350","key":"10.1016\/j.jneuroim.2024.578315_bb0135","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(02)12023-X","article-title":"Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial","volume":"360","author":"Hartung","year":"2002","journal-title":"Lancet."},{"issue":"16","key":"10.1016\/j.jneuroim.2024.578315_bb0140","doi-asserted-by":"crossref","first-page":"e1546","DOI":"10.1212\/WNL.0000000000012700","article-title":"Safety of ocrelizumab in patients with relapsing and primary progressive multiple sclerosis","volume":"97","author":"Hauser","year":"2021","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.jneuroim.2024.578315_bb0145","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1002\/eji.201470045","article-title":"B cells in multiple sclerosis: good or bad guys?: an article for 28 may 2014 - world MS day 2014","volume":"44","author":"Hoffmann","year":"2014","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jneuroim.2024.578315_bb0150","series-title":"MS: Primary Results of a Phase II Trial","first-page":"2023","article-title":"Efficacy and Safety of Fenebrutinib, a Noncovalent, Reversible BTK Inhibitor","author":"Hua","year":"2024"},{"issue":"4","key":"10.1016\/j.jneuroim.2024.578315_bb0160","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1007\/s00415-019-09489-5","article-title":"A focus on secondary progressive multiple sclerosis (SPMS): challenges in diagnosis and definition","volume":"268","author":"Inojosa","year":"2021","journal-title":"J. Neurol."},{"issue":"1\u20132","key":"10.1016\/j.jneuroim.2024.578315_bb0165","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s10863-014-9571-y","article-title":"Idebenone and neuroprotection: antioxidant, pro-oxidant, or electron carrier?","volume":"47","author":"Jaber","year":"2015","journal-title":"J. Bioenerg. Biomembr."},{"issue":"5","key":"10.1016\/j.jneuroim.2024.578315_bb0170","doi-asserted-by":"crossref","first-page":"e783","DOI":"10.1212\/WNL.0000000000011242","article-title":"Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years","volume":"96","author":"Kalincik","year":"2021","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.jneuroim.2024.578315_bb0175","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1136\/jnnp-2014-310024","article-title":"Factors influencing long-term outcomes in relapsing-remitting multiple sclerosis: PRISMS-15","volume":"86","author":"Kappos","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"9","key":"10.1016\/j.jneuroim.2024.578315_bb0180","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","article-title":"Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing Multiple Sclerosis in a pooled analysis of 2 randomized clinical trials","volume":"77","author":"Kappos","year":"2020","journal-title":"JAMA Neurol."},{"issue":"3","key":"10.1016\/j.jneuroim.2024.578315_bb0185","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/WCO.0000000000000206","article-title":"Classification, diagnosis, and differential diagnosis of multiple sclerosis","volume":"28","author":"Katz","year":"2015","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.jneuroim.2024.578315_bb0190","article-title":"Estimated prevalence of secondary progressive multiple sclerosis in the USA and Europe: results from a systematic literature search (P2. 380)","author":"Khurana","year":"2018","journal-title":"AAN Enterpri"},{"key":"10.1016\/j.jneuroim.2024.578315_bb0195","doi-asserted-by":"crossref","first-page":"102434","DOI":"10.1016\/j.msard.2020.102434","article-title":"Idebenone does not inhibit disability progression in primary progressive MS","volume":"45","author":"Kosa","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"5","key":"10.1016\/j.jneuroim.2024.578315_bb0200","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41582-023-00800-7","article-title":"Bruton tyrosine kinase inhibitors for multiple sclerosis","volume":"19","author":"Kr\u00e4mer","year":"2023","journal-title":"Nat. Rev. Neurol."},{"issue":"5","key":"10.1016\/j.jneuroim.2024.578315_bb0205","doi-asserted-by":"crossref","first-page":"e279","DOI":"10.1212\/NXI.0000000000000279","article-title":"The topographical model of multiple sclerosis: a dynamic visualization of disease course","volume":"3","author":"Krieger","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"Pt 11","key":"10.1016\/j.jneuroim.2024.578315_bb0210","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1093\/brain\/awh641","article-title":"Cortical demyelination and diffuse white matter injury in multiple sclerosis","volume":"128","author":"Kutzelnigg","year":"2005","journal-title":"Brain."},{"issue":"3","key":"10.1016\/j.jneuroim.2024.578315_bb0215","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s40265-022-01672-9","article-title":"Ocrelizumab: a review in Multiple Sclerosis","volume":"82","author":"Lamb","year":"2022","journal-title":"Drugs."},{"issue":"8\u20139","key":"10.1016\/j.jneuroim.2024.578315_bb0230","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1081\/NCN-200027547","article-title":"Dihydroorotate dehydrogenase mRNA and protein expression analysis in normal and drug-resistant cells","volume":"23","author":"L\u00f6ffler","year":"2004","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"issue":"9","key":"10.1016\/j.jneuroim.2024.578315_bb0235","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2147\/ITT.S240874","article-title":"Bruton\u2019s tyrosine kinase inhibitors: a new therapeutic target for the treatment of SLE?","volume":"2","author":"Lorenzo-Vizcaya","year":"2020","journal-title":"Immunotargets Ther."},{"issue":"Pt 9","key":"10.1016\/j.jneuroim.2024.578315_bb0240","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1093\/brain\/aww173","article-title":"MSBase study group. Defining secondary progressive multiple sclerosis","volume":"139","author":"Lorscheider","year":"2016","journal-title":"Brain."},{"issue":"3","key":"10.1016\/j.jneuroim.2024.578315_bb0245","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: the 2013 revisions","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.jneuroim.2024.578315_bb0250","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1093\/brain\/awac016","article-title":"How patients with multiple sclerosis acquire disability","volume":"145","author":"Lublin","year":"2022","journal-title":"Brain."},{"issue":"4","key":"10.1016\/j.jneuroim.2024.578315_bb0255","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00401-018-1818-y","article-title":"Progressive multiple sclerosis patients show substantial lesion activity that correlates with clinical disease severity and sex: a retrospective autopsy cohort analysis","volume":"135","author":"Luchetti","year":"2018","journal-title":"Acta Neuropathol."},{"issue":"Pt 4","key":"10.1016\/j.jneuroim.2024.578315_bb0260","first-page":"1089","article-title":"Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology","volume":"130","author":"Magliozzi","year":"2007","journal-title":"Brain."},{"issue":"1\u20132","key":"10.1016\/j.jneuroim.2024.578315_bb0265","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jns.2014.06.051","article-title":"Is it time for a new global classification of multiple sclerosis?","volume":"344","author":"Melcon","year":"2014","journal-title":"J. Neurol. Sci."},{"issue":"3","key":"10.1016\/j.jneuroim.2024.578315_bb0270","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s004150050066","article-title":"Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome","volume":"244","author":"Millefiorini","year":"1997","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2024.578315_bb0275","doi-asserted-by":"crossref","first-page":"102129","DOI":"10.1016\/j.msard.2020.102129","article-title":"Vidofludimus calcium, a next generation DHODH inhibitor for the treatment of relapsing-remitting multiple sclerosis","volume":"43","author":"Muehler","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"7","key":"10.1016\/j.jneuroim.2024.578315_bb0280","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrneurol.2017.81","article-title":"Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis","volume":"13","author":"Muraro","year":"2017","journal-title":"Nat. Rev. Neurol."},{"issue":"1","key":"10.1016\/j.jneuroim.2024.578315_bb0295","first-page":"A12","article-title":"The prevalence of multiple sclerosis in 3 US communities","volume":"7","author":"Noonan","year":"2010","journal-title":"Prev. Chronic Dis."},{"issue":"5","key":"10.1016\/j.jneuroim.2024.578315_bb0300","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1358\/dof.2022.47.5.3400574","article-title":"Tolebrutinib. Bruton tyrosine kinase (BTK) inhibitor treatment of multiple sclerosis","volume":"47","author":"Orlandi","year":"2022","journal-title":"Drugs Future"},{"issue":"1","key":"10.1016\/j.jneuroim.2024.578315_bb0305","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3164\/jcbn.11-005FR","article-title":"Lipoic acid: energy metabolism and redox regulation of transcription and cell signaling","volume":"48","author":"Packer","year":"2011","journal-title":"J. Clin. Biochem. Nutr."},{"issue":"20","key":"10.1016\/j.jneuroim.2024.578315_bb0310","doi-asserted-by":"crossref","first-page":"e144624","DOI":"10.1172\/jci.insight.144624","article-title":"Epstein-Barr virus-specific T cell therapy for progressive multiple sclerosis","volume":"5","author":"Pender","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.jneuroim.2024.578315_bb0315","doi-asserted-by":"crossref","first-page":"104125","DOI":"10.1016\/j.msard.2022.104125","article-title":"Updates on efficacy and safety outcomes of new and emerging disease modifying therapies and stem cell therapy for Multiple Sclerosis: a review","volume":"68","author":"Peterson","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jneuroim.2024.578315_bb0290","series-title":"Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton\u2019s Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)ClinicalTrials.gov ID NCT04411641","year":"2023"},{"key":"10.1016\/j.jneuroim.2024.578315_bb0325","series-title":"Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton\u2019s Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS) (PERSEUS) ClinicalTrials.gov ID NCT04458051","year":"2024"},{"issue":"9","key":"10.1016\/j.jneuroim.2024.578315_bb0330","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S1474-4422(21)00237-4","article-title":"Tolebrutinib phase 2b study group. Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial","volume":"20","author":"Reich","year":"2021","journal-title":"Lancet Neurol."},{"issue":"17","key":"10.1016\/j.jneuroim.2024.578315_bb0335","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1517\/14656560903426189","article-title":"Ibudilast: a review of its pharmacology, efficacy and safety in respiratory and neurological disease","volume":"10","author":"Rolan","year":"2009","journal-title":"Expert. Opin. Pharmacother."},{"issue":"4","key":"10.1016\/j.jneuroim.2024.578315_bb0340","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S1474-4422(06)70410-0","article-title":"Secondary progressive multiple sclerosis: current knowledge and future challenges","volume":"5","author":"Rovaris","year":"2006","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.jneuroim.2024.578315_bb0345","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1136\/jnnp-2012-304333","article-title":"Onset of secondary progressive phase and long-term evolution of multiple sclerosis","volume":"85","author":"Scalfari","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2024.578315_bb0350","doi-asserted-by":"crossref","first-page":"106941","DOI":"10.1016\/j.cct.2022.106941","article-title":"N-acetyl cysteine as a neuroprotective agent in progressive Multiple Sclerosis (NACPMS) trial: study protocol for a randomized, double-blind, placebo-controlled add-on phase 2 trial","volume":"122","author":"Schoeps","year":"2022","journal-title":"Contemp. Clin. Trials"},{"issue":"9","key":"10.1016\/j.jneuroim.2024.578315_bb0355","doi-asserted-by":"crossref","first-page":"101497","DOI":"10.1016\/j.disamonth.2022.101497","article-title":"Pathogenesis and management of multiple sclerosis revisited","volume":"69","author":"Shah","year":"2023","journal-title":"Dis. Mon."},{"key":"10.1016\/j.jneuroim.2024.578315_bb0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104899","article-title":"Defining progression independent of relapse activity (PIRA) in adult patients with relapsing multiple sclerosis: a systematic review\u2730","volume":"78","author":"Sharrad","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.jneuroim.2024.578315_bb0365","first-page":"23","article-title":"Bruton\u2019s tyrosine kinase inhibitors in the treatment of multiple sclerosis","volume":"32","author":"Shulga","year":"2023","journal-title":"Postep. Psychiatr. Neurol."},{"issue":"319","key":"10.1016\/j.jneuroim.2024.578315_bb0370","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.neuroscience.2016.01.042","article-title":"A randomized, placebo-controlled trial of the benzoquinone idebenone in a mouse model of OPA1-related dominant optic atrophy reveals a limited therapeutic effect on retinal ganglion cell dendropathy and visual function","volume":"5","author":"Smith","year":"2016","journal-title":"Neuroscience."},{"issue":"22","key":"10.1016\/j.jneuroim.2024.578315_bb0375","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1212\/WNL.0000000000003987","article-title":"Autologous hematopoietic stem cell transplantation in multiple sclerosis: A meta-analysis","volume":"88","author":"Sormani","year":"2017","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.jneuroim.2024.578315_bb0380","doi-asserted-by":"crossref","first-page":"e374","DOI":"10.1212\/NXI.0000000000000374","article-title":"Lipoic acid in secondary progressive MS: a randomized controlled pilot trial","volume":"4","author":"Spain","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"6","key":"10.1016\/j.jneuroim.2024.578315_bb0385","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.kint.2021.10.010","article-title":"Lipoic acid supplementation associated with neural epidermal growth factor-like 1 (NELL1)-associated membranous nephropathy","volume":"100","author":"Spain","year":"2021","journal-title":"Kidney Int."},{"issue":"6","key":"10.1016\/j.jneuroim.2024.578315_bb0390","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/nri2548","article-title":"A molecular trio in relapse and remission in multiple sclerosis","volume":"9","author":"Steinman","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jneuroim.2024.578315_bb0395","author":"Study to Evaluate Efficacy"},{"key":"10.1016\/j.jneuroim.2024.578315_bb0400","author":"Study to Study to Evaluate the Efficacy"},{"issue":"9","key":"10.1016\/j.jneuroim.2024.578315_bb0405","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s40263-018-0568-7","article-title":"Ocrelizumab: a review in Multiple Sclerosis","volume":"32","author":"Syed","year":"2018","journal-title":"CNS Drugs"},{"issue":"6","key":"10.1016\/j.jneuroim.2024.578315_bb0410","doi-asserted-by":"crossref","first-page":"967","DOI":"10.3390\/antiox10060967","article-title":"N-acetylcysteine (NAC): impacts on human health","volume":"10","author":"Ten\u00f3rio","year":"2021","journal-title":"Antioxidants (Basel)."},{"issue":"Suppl. 2","key":"10.1016\/j.jneuroim.2024.578315_bb0415","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1007\/s100720100044","article-title":"The differential diagnosis of multiple sclerosis: classification and clinical features of relapsing and progressive neurological syndromes","volume":"22","author":"Trojano","year":"2001","journal-title":"Neurol. Sci."},{"issue":"2","key":"10.1016\/j.jneuroim.2024.578315_bb0420","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/jamaneurol.2022.4655","article-title":"Association of early progression independent of relapse activity with long-term disability after a first demyelinating event in multiple sclerosis","volume":"80","author":"Tur","year":"2023","journal-title":"JAMA Neurol."},{"issue":"5","key":"10.1016\/j.jneuroim.2024.578315_bb0425","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/ana.25463","article-title":"Silent progression in disease activity-free relapsing multiple sclerosis","volume":"85","author":"University of California, San Francisco MS-EPIC Team","year":"2019","journal-title":"Ann. Neurol."},{"issue":"9","key":"10.1016\/j.jneuroim.2024.578315_bb0430","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1212\/01.WNL.0000091861.27246.9E","article-title":"[alpha]B-crystallin genotype has impact on the multiple sclerosis phenotype","volume":"61","author":"van Veen","year":"2003","journal-title":"Neurology."},{"key":"10.1016\/j.jneuroim.2024.578315_bb0435","first-page":"11","article-title":"Masitinib in primary progressive (PPMS) and non-active secondary progressive (nSPMS) multiple sclerosis: results from phase 3 study AB07002","author":"Vermersch","year":"2020","journal-title":"MSVirtual2020."},{"issue":"12","key":"10.1016\/j.jneuroim.2024.578315_bb0440","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1471-2377-12-36","article-title":"Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study","volume":"12","author":"Vermersch","year":"2012","journal-title":"BMC Neurol."},{"issue":"3","key":"10.1016\/j.jneuroim.2024.578315_bb0445","doi-asserted-by":"crossref","first-page":"e1148","DOI":"10.1212\/NXI.0000000000001148","article-title":"Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis: A Randomized, Phase 3, Clinical Trial","volume":"9","author":"Vermersch","year":"2022","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"1","key":"10.1016\/j.jneuroim.2024.578315_bb0450","doi-asserted-by":"crossref","first-page":"25","DOI":"10.7453\/gahmj.2013.011","article-title":"Adverse effects of high doses of intravenous alpha lipoic acid on liver mitochondria","volume":"3","author":"Vigil","year":"2014","journal-title":"Glob Adv Health Med."},{"issue":"10","key":"10.1016\/j.jneuroim.2024.578315_bb0455","doi-asserted-by":"crossref","first-page":"e1029","DOI":"10.1212\/WNL.0000000000007035","article-title":"The prevalence of MS in the United States: a population-based estimate using health claims data","volume":"92","author":"Wallin","year":"2019","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.jneuroim.2024.578315_bb0460","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.mayocp.2013.11.002","article-title":"Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies","volume":"89","author":"Wingerchuk","year":"2014","journal-title":"Mayo Clin. Proc."},{"issue":"354","key":"10.1016\/j.jneuroim.2024.578315_bb0465","doi-asserted-by":"crossref","first-page":"i3518","DOI":"10.1136\/bmj.i3518","article-title":"Disease modifying therapies for relapsing multiple sclerosis","volume":"22","author":"Wingerchuk","year":"2016","journal-title":"BMJ."},{"issue":"Pt 7","key":"10.1016\/j.jneuroim.2024.578315_bb0470","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1093\/brain\/122.7.1211","article-title":"The mechanisms of lesion genesis in multiple sclerosis?","volume":"122","author":"Wolinsky","year":"1999","journal-title":"Brain."},{"issue":"1","key":"10.1016\/j.jneuroim.2024.578315_bb0475","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ncl.2017.08.006","article-title":"Progressive forms of Multiple Sclerosis: distinct entity or age-dependent phenomena","volume":"36","author":"Zeydan","year":"2018","journal-title":"Neurol. Clin."},{"issue":"2","key":"10.1016\/j.jneuroim.2024.578315_bb0480","doi-asserted-by":"crossref","first-page":"e435","DOI":"10.1212\/NXI.0000000000000435","article-title":"Cervical spinal cord atrophy: an early marker of progressive MS onset","volume":"5","author":"Zeydan","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"7","key":"10.1016\/j.jneuroim.2024.578315_bb0485","doi-asserted-by":"crossref","DOI":"10.2196\/19598","article-title":"Gaining first insights on secondary progressive Multiple Sclerosis patients treated with Siponimod in clinical routine: protocol of the noninterventional study AMASIA","volume":"9","author":"Ziemssen","year":"2020","journal-title":"JMIR Res Protoc."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016557282400033X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016557282400033X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T07:22:18Z","timestamp":1715325738000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016557282400033X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":89,"alternative-id":["S016557282400033X"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2024.578315","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent advances in the treatment of primary and secondary progressive Multiple Sclerosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2024.578315","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"578315"}}